Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Hypoxic-ischemic encephalopathy
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Aug 07, 2024
Q2 2024 update
Jul 25, 2024
Neuren to participate in upcoming US investor conferences
Jul 19, 2024
Ceasing to be a substantial holder
Jul 19, 2024
Neuren receives Rare Pediatric Disease Designation from FDA
Jul 02, 2024
Final Director's Interest Notice - T Scott
Jun 17, 2024
Application for quotation of securities - NEU
Jun 13, 2024
Change of Director's Interest Notice - J Basile
May 29, 2024
Corporate Presentation, 29 May 2024
May 28, 2024
Results of Meeting
May 28, 2024
AGM Chair Address & CEO Presentation
Previous
1
2
3
4
5
6
7
Next
